Literature DB >> 26360055

Challenges and opportunities for non-antibody scaffold drugs.

Rodrigo Vazquez-Lombardi1, Tri Giang Phan1, Carsten Zimmermann2, David Lowe3, Lutz Jermutus4, Daniel Christ5.   

Abstract

The first candidates from the promising class of small non-antibody protein scaffolds are now moving into clinical development and practice. Challenges remain, and scaffolds will need to be further tailored toward applications where they provide real advantages over established therapeutics to succeed in a rapidly evolving drug development landscape.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Mesh：

Substances：

Year:  2015        PMID： 26360055     DOI： 10.1016/j.drudis.2015.09.004

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  66 in total

1.  Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties.

Authors:  Lynn E Macdonald; Karoline A Meagher; Matthew C Franklin; Natasha Levenkova; Johanna Hansen; Ashok T Badithe; Maggie Zhong; Pamela Krueger; Ashique Rafique; Naxin Tu; James Shevchuk; Saurabh Wadhwa; George Ehrlich; Joannie Bautista; Craig Grant; Lakeisha Esau; William T Poueymirou; Wojtek Auerbach; Lori Morton; Robert Babb; Gang Chen; Tammy Huang; Douglas MacDonald; Kenneth Graham; Cagan Gurer; Vera A Voronina; John R McWhirter; Chunguang Guo; George D Yancopoulos; Andrew J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-26       Impact factor: 11.205

2.  Massively parallel de novo protein design for targeted therapeutics.

Authors:  Aaron Chevalier; Daniel-Adriano Silva; Gabriel J Rocklin; Derrick R Hicks; Renan Vergara; Patience Murapa; Steffen M Bernard; Lu Zhang; Kwok-Ho Lam; Guorui Yao; Christopher D Bahl; Shin-Ichiro Miyashita; Inna Goreshnik; James T Fuller; Merika T Koday; Cody M Jenkins; Tom Colvin; Lauren Carter; Alan Bohn; Cassie M Bryan; D Alejandro Fernández-Velasco; Lance Stewart; Min Dong; Xuhui Huang; Rongsheng Jin; Ian A Wilson; Deborah H Fuller; David Baker
Journal:  Nature       Date:  2017-09-27       Impact factor: 49.962

Review 3.  Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics.

Authors:  Alessandro Zorzi; Sara Linciano; Alessandro Angelini
Journal:  Medchemcomm       Date:  2019-06-06       Impact factor: 3.597

4.  Controlled conductivity at low pH in Protein L chromatography enables separation of bispecific and other antibody formats by their binding valency.

Authors:  Chen Chen; Tetsuya Wakabayashi; Masaru Muraoka; Feng Shu; Chia Wei Shan; Chong Chor Kun; Ching Tim Jang; Ishin Soehano; Yuichiro Shimizu; Tomoyuki Igawa; Jun-Ichi Nezu
Journal:  MAbs       Date:  2019-03-21       Impact factor: 5.857

Review 5.  Unintended effects of drug carriers: Big issues of small particles.

Authors:  Hamideh Parhiz; Makan Khoshnejad; Jacob W Myerson; Elizabeth Hood; Priyal N Patel; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

6.  High-throughput developability assays enable library-scale identification of producible protein scaffold variants.

Authors:  Alexander W Golinski; Katelynn M Mischler; Sidharth Laxminarayan; Nicole L Neurock; Matthew Fossing; Hannah Pichman; Stefano Martiniani; Benjamin J Hackel
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-08       Impact factor: 11.205

7.  Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies.

Authors:  Sarah Ahn; Jingjing Li; Chuang Sun; Keliang Gao; Koichi Hirabayashi; Hongxia Li; Barbara Savoldo; Rihe Liu; Gianpietro Dotti
Journal:  Cancer Immunol Res       Date:  2019-03-06       Impact factor: 11.151

8.  Engineered Fn3 protein has targeted therapeutic effect on mesothelin-expressing cancer cells and increases tumor cell sensitivity to chemotherapy.

Authors:  Allison R Sirois; Daniela A Deny; Yanxuan Li; Yacine D Fall; Sarah J Moore
Journal:  Biotechnol Bioeng       Date:  2019-11-12       Impact factor: 4.530

Review 9.  Engineered protein scaffolds as leads for synthetic inhibitors of protein-protein interactions.

Authors:  Michael G Wuo; Paramjit S Arora
Journal:  Curr Opin Chem Biol       Date:  2018-05-24       Impact factor: 8.822

Review 10.  Paradigm shift in bacteriophage-mediated delivery of anticancer drugs: from targeted 'magic bullets' to self-navigated 'magic missiles'.

Authors:  Valery A Petrenko; James W Gillespie
Journal:  Expert Opin Drug Deliv       Date:  2016-08-05       Impact factor: 6.648
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.